Clinical trials: Cancer Patients and Physical Activity
Breast Neoplasms, Autonomic Nervous System Diseases
Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients
The aim of this study is to evaluate the effect of exercise training in the autonomic nervous system activity in breast cancer patients, who underwent doxorubicin medication.
- Trial name
- NCT02584712
- Testing
- Combined Exercise Training
- Volunteers
- 18 people
- Sponsor
- Federal University of Maranhao
Breast Cancer
Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation
The purpose of this study is to study if a patients follows an exercise program specifically designed for them during the time of their treatment after surgery.
- Trial name
- NCT01157767
- Testing
- standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Advanced Solid Tumor
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
- Trial name
- NCT03457532
- Testing
- Gumarontinib Tablets
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Malignant Childhood Neoplasm
Effectiveness of an Integrated Programme in Promoting the Regular Physical Activity Among Childhood Cancer Survivors
Background.There is some evidence that engaging in regular moderate-intensity physical activity may help ameliorate cancer-related fatigue experienced by childhood cancer survivors, which eventually improve their quality of life.
- Trial name
- NCT01803672
- Testing
- health talk and adventure-based training
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
NSCLC
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Alflutinib Mesylate Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model.
- Trial name
- NCT02973763
- Testing
- Alflutinib
- Volunteers
- 14 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Breast Cancer
The EMBRACE Study The EMBRACE Study
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart.
- Trial name
- EMBRACE (NCT04467411)
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Myelodysplastic Syndrome, Cytopenia
Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
Somatic mutations as seen in myeloid malignancies can also be detected in healthy, elderly individuals (clonal hematopoiesis of indeterminate potential, CHIP), in patients with unex-plained cytopenia, that do not fulfill the…
- Trial name
- HemEx (NCT06773871)
- Testing
- Exercise, Control
- Where
- 2 sites in Denmark
- Volunteers
- 36 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Malignant Neoplasms
Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors
Phase I study of YKYY031 for injection in patients with advanced solid tumors
- Trial name
- YKYY031，tumors (NCT07631793)
- Testing
- YKYY031 group (the first stage), YKYY031 group (the second stage)
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
Breast Cancer, Cardiotoxicity
Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients
Breast cancer is a chronic disease that has seen a boom in research into its treatments, improvements and effects in recent decades.
- Conditions
- Breast Cancer, Cardiotoxicity, Autonomic Imbalance
- Trial name
- NCT05040867
- Testing
- Physical exercise program
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- GO fit Lab- Ingesport
HPV Infection
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1.
- Trial name
- 9vHPV-BCG (NCT06959563)
- Testing
- 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid…
- Conditions
- Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas
- Trial name
- NCT07713732
- Testing
- TLN-499, Venetoclax
- Where
- 3 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Treeline Biosciences, Inc.
Breast Neoplasms, Sarcopenia
Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors
This study evaluates the comparative effectiveness of a multi-modal facility-based rehabilitation program (therapist-led resistance exercise and relaxation training) versus a self-directed home-based resistance exercise program…
- Trial name
- exercise (NCT07465393)
- Testing
- Multimodal Resistance and Relaxation Training, Home-Based Resistance Exercise Training
- Where
- Taiwan
- Volunteers
- 66 people
- Sponsor
- Valeria Chiu
Metastatic Colorectal Cancer
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
To document the antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00459901
- Testing
- Erlotinib and capecitabine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Peter Kozuch
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Ovarian Cancer, Primary Peritoneal Carcinoma
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of…
- Trial name
- NCT00083928
- Testing
- Å6 subcutaneous injection
- Where
- 24 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ångstrom Pharmaceuticals
Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma
Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy
- Trial name
- NCT03031483
- Testing
- clarithromycin and lenalidomide
- Where
- 10 sites in Austria, Italy and 1 more
- Volunteers
- 44 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Advanced Solid Tumor
A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors
The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors，determine the maximum tolerated dose (MTD) or maximum drug dose（MAD）of QLS1209, identify a…
- Trial name
- NCT06872580
- Testing
- QLS1209
- Volunteers
- 149 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
The purpose of this study is to assess the efficacy and safety of sitravatinib plus tislelizumab or combination with nab-paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC) patients.
- Trial name
- SPARK (NCT04734262)
- Testing
- Sitravatinib, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Fudan University
Solid Tumors
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
- Trial name
- NCT06386146
- Testing
- JAB-30355
- Where
- 15 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.